Regen BioPharma (Regen BioPharma) Total Stockholders Equity : $-5.18 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Total Stockholders Equity?

Regen BioPharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-5.18 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Regen BioPharma's Book Value per Share for the quarter that ended in Mar. 2024 was $-1.38. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Regen BioPharma's Debt-to-Equity for the quarter that ended in Mar. 2024 was -0.13.

Regen BioPharma Total Stockholders Equity Historical Data

The historical data trend for Regen BioPharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Total Stockholders Equity Chart

Regen BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Stockholders Equity

Get a 7-Day Free Trial

-10.91

-7.34

-13.49

-8.04

-5.10

Regen BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															-	-5.03	-5.10	-5.24	-5.18

Regen BioPharma (OTCPK:RGBP) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Regen BioPharma's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-5.176	-	0)	/	3.75056
	=	-1.38

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Regen BioPharma's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.55	+	0.144)	/	-5.176
	=	-0.13

Regen BioPharma Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma (Regen BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

RGBPP.PFD:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.